Stryker lowers expected tariff impact to $175M

The medtech firm, which previously forecast a $200 million tariff impact for 2025, also raised its earnings outlook, citing strength in procedure demand.

By Elise Reuter • Aug. 1, 2025

Dexcom raises sales expectations, discusses G8 plans

Outgoing CEO Kevin Sayer expects expanding coverage of Dexcom’s glucose sensors for people with Type 2 diabetes and over-the-counter devices to drive future growth.

By Elise Reuter • July 31, 2025

Medtech firms slash expected tariff charges

This earnings season, top medical device companies have dramatically reduced their expectations for tariff impacts in 2025. Check out MedTech Dive’s coverage.

By Ricky Zipp • July 30, 2025

Siemens Healthineers cuts tariff impact after trade talk breakthrough

The company predicted a full-year impact of 200 million to 250 million euros, down from its previous forecast of up to 300 million euros.

By Nick Paul Taylor • July 30, 2025

Quest, Labcorp downplay ‘Big Beautiful Bill’ impact

Executives at the laboratory companies said they expect the effects on testing services from the Republicans’ tax and domestic policy bill, including cuts to Medicaid, will be minimal.

By Susan Kelly • July 29, 2025

Philips lowers expected tariff hit to 150M to 200M euros

The company previously forecast an up to 300 million euro tariff impact in 2025 before the U.S. struck agreements with China and the European Union.

By Elise Reuter • July 29, 2025

Edwards loses longtime TAVR leader Larry Wood

Wood, who helped build Edwards’ TAVR business, will become CEO of Procept BioRobotics. Edwards also raised its sales and earnings outlook for the full year.

By Susan Kelly • July 25, 2025

Boston Scientific halves expected tariff hit

The company now expects a tariff charge of $100 million this year, down from a $200 million impact forecast on the company’s first-quarter earnings call.

By Ricky Zipp • July 23, 2025

Intuitive Surgical tempers tariff impact expectations

Executives also addressed Medicaid concerns and competition from third-party suppliers of remanufactured surgical instruments on an earnings call.

By Susan Kelly • July 23, 2025

Abbott lowers sales forecast on diagnostics decline, US funding cuts

Medical device sales remained a bright spot for the company, however, with more than 20% growth in diabetes devices.

By Elise Reuter • July 17, 2025

‘We are not rolling over’: J&J electrophysiology unit rebounds amid PFA rivalry

The division returned to growth in the second quarter after declining over the previous three months. Now, can the healthcare giant catch up with its rivals in pulsed field ablation?

By Ricky Zipp • July 16, 2025

J&J may take a softer tariff hit after US-China pause, CFO says

Joseph Wolk told an investor conference that the company’s tariff estimate is a “moving target” as trade talks continue with China and Europe and Section 232 investigations are ongoing.

By Susan Kelly • June 4, 2025

Why Medtronic plans to spin out its diabetes business

While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on segments with higher margins.

By Elise Reuter • May 22, 2025

Cost cuts, production shifts: How medtech firms are managing tariffs

Many companies forecast specific tariff charges. Then the White House and China agreed to a 90-day pause in their trade standoff.

By Susan Kelly • May 22, 2025

Medtronic plans to spin off diabetes business within 18 months

CEO Geoff Martha told investors the split simplifies Medtronic’s portfolio, while creating a stand-alone diabetes tech competitor.

By Ricky Zipp • May 21, 2025

Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products

In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.

By Elise Reuter • May 16, 2025

Andrew Witty steps down as UnitedHealth CEO

Witty’s departure was surprising, though it follows a sharp downturn in the healthcare juggernaut’s financial outlook. He is being replaced by Stephen Hemsley, the chair of UnitedHealth’s board and a previous chief executive.

By Rebecca Pifer • May 13, 2025

Solventum’s projected $100M tariff hit prevents earnings increase

CEO Bryan Hanson said tariffs have given “a higher sense of urgency” to the company’s existing efforts to regionalize its supply chains.

By Nick Paul Taylor • May 12, 2025

New Insulet CEO Ashley McEvoy sets priorities

The diabetes tech company raised its expectations for revenue and gross margins, despite the impact of tariffs.

By Elise Reuter • May 9, 2025

SEC ends probe of Illumina’s Grail acquisition

The DNA sequencing company also cut its 2025 earnings outlook to reflect the impact of tariffs on its business.

By Susan Kelly • May 9, 2025

Masimo says cyberattack has impacted its ability to fulfill orders

The maker of patient monitoring devices is working to bring the affected portions of its network back online and restore normal business operations.

By David Jones • May 8, 2025

Siemens Healthineers lowers earnings forecast on expected tariff hit

The company expects a tariff impact of up to 300 million euros, with the biggest hit from European goods going to the U.S.

By Nick Paul Taylor • May 8, 2025

Philips cuts earnings forecast after calculating $340M tariff hit

CEO Roy Jakobs said tariff impacts require the company to accelerate localization of production in the U.S.

By Nick Paul Taylor • May 6, 2025

Zimmer Biomet expects $60M to $80M tariff impact this year

The orthopedics company lowered its earnings forecast, accounting for the tariffs and closing the acquisition of Paragon 28.

By Elise Reuter • May 6, 2025

Cardinal Health cuts employees to offset up to $300M tariff charge

Executives said Thursday that the company has already laid off employees to help mitigate the effects of the Trump administration’s tariff policies.

By Ricky Zipp • May 2, 2025